En miljöpremie i läkemedelsförmånssystemet : Lösningen på läkemedelsföretagens miljöförstöring?

Sammanfattning

In May 2021 the Swedish government decided to establish a trial period for an environmental bonus within the swedish reimbursement system, with the purpose to reduce the emissions of antibiotics and carbon dioxide from the pharmaceutical industry. This thesis examines the effect of the bonus on the pharmaceutical market and whether the goal set by the government can be met based on economic theory. By an in-depth analysis of the generic market, the implementation of the environmental premium is examined on the basis of the Bertrand model. The thesis finds that the environmental bonus will give different outcomes depending on the number of competing firms on the market. The main conclusion is that an environmental bonus will, in most cases, lead to higher prices for medicines. The thesis also finds that the bonus would probably give the best results in the substitution groups where many firms compete.